313 related articles for article (PubMed ID: 19039321)
1. Pathogenesis of myeloma bone disease.
Roodman GD
Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
3. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
4. Novel targets for myeloma bone disease.
Roodman GD
Expert Opin Ther Targets; 2008 Nov; 12(11):1377-87. PubMed ID: 18851694
[TBL] [Abstract][Full Text] [Related]
5. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
8. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
9. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
10. The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R
Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
[TBL] [Abstract][Full Text] [Related]
11. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
[TBL] [Abstract][Full Text] [Related]
12. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease and treatment options.
Yeh HS; Berenson JR
Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
[TBL] [Abstract][Full Text] [Related]
14. [Myeloma bone disease and RANKL signaling].
Abe M
Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
[TBL] [Abstract][Full Text] [Related]
15. Myeloma and Bone Disease.
Panaroni C; Yee AJ; Raje NS
Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
[TBL] [Abstract][Full Text] [Related]
16. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
17. [Multiple myeloma].
Abe M
Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
[TBL] [Abstract][Full Text] [Related]
18. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Terpos E; Dimopoulos MA; Sezer O
Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
20. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
